Clinical Data Of Moderna's Investigational MRNA Therapy Gets Published In Nature

(RTTNews) - Pharmaceutical company, Moderna, Inc. (MRNA), Wednesday announced that the interim data on the company's mRNA-3927, an investigational mRNA therapy for propionic acidemia or PA, was published in Nature magazine.

PA is a rare, inherited metabolic disorder that results from the body's inability to process certain parts of proteins and lipids due to a specific enzyme deficiency.

During the trial to study the safety, pharmacodynamics, and pharmacokinetics of mRNA-3927 in participants aged one year and older with genetically confirmed PA, a 70 percent reduction in metabolic decompensation events was observed during the treatment period.

The company further said that the therapy has been reportedly well tolerated in trial participants, with no dose-limiting toxicities observed. However, fifteen participants reported treatment-emergent adverse events and eight participants reported serious adverse events which were unrelated to mRNA-3927.

Currently, Moderna's stock is gaining 0.22 percent, to $103.88 on the Nasdaq.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.